7 Assets With Negative Performances

- By Tiziano Frateschi

While gurus hold positions in these companies, the stock price and returns continue to fall. These are the worst-performing stocks over the last three months with a long-term presence in more than four gurus' portfolios.


Tesaro Inc. (TSRO) had a negative performance of 17.4% over the last six months. Three mutual funds hold the stock with a total weight of 0.38% on their portfolios.

The company has a market cap of $6.96 billion, and the stock is trading with a price-sales (P/S) ratio of 128.07. The price of $129.13 is 33.07% below its 52-week high and 55.09% above its 52-week low. Over the last 10 years, it returned a gain of 47%.

The return on equity (ROE) of -110.69% and return on assets (ROA) of -72.44% are underperforming 80% of other companies in the Global Biotechnology industry.

Vanguard Health Care Fund (Trades, Portfolio) with 1.19% of outstanding shares is the largest investor among the gurus followed by Steven Cohen (Trades, Portfolio) with 0.73%, Pioneer Investments (Trades, Portfolio) with 0.2%, Leon Cooperman (Trades, Portfolio) with 0.05% and Paul Tudor Jones (Trades, Portfolio) with 0.01%.

Fresh Del Monte Produce Inc. (FDP) had a negative performance of 17.6% over the last six months. Three mutual funds are holding the stock with a total weight of 0.08% on their portfolios.

The company has a market cap of $2.61 billion, and the stock is trading with a P/S ratio of 0.68. The price of $50.98 is 23.75% below its 52-week high and 4.32% above its 52-week low. Over the last 10 years, it returned a loss of 8%.

The ROE of 10.61% and ROA of 7.20% are outperforming 58% of other companies in the Global Farm Products industry.

The largest shareholder among the gurus is Jim Simons (Trades, Portfolio) with 1.23% followed by Chuck Royce (Trades, Portfolio) with 0.44%, Joel Greenblatt (Trades, Portfolio) with 0.08%, Jones with 0.02% and Caxton Associates (Trades, Portfolio) with 0.01%.

Dermira Inc. (DERM) had a negative performance of 6.0% over the last six months. Three mutual funds are holding the stock with a total weight of 0.52% on their portfolios.

The company has a market cap of $1.19 billion, and the stock is trading with a P/S ratio of 43.12. The price of $28.55 is 26.32% below its 52-week high and 11.39% above its 52-week low. Over the last 10 years, it returned a loss of 6%.

The ROE of -33.79% and ROA of -28.47% are outperforming 51% of other companies in the Global Biotechnology industry.